Why specialist clinics need a documented position
1. Patient images and specialist records are high-sensitivity data
Clinical photographs, aesthetic before-and-after images, fertility records, ophthalmic scans and diagnostic images can be highly sensitive. Where AI processes patient images, identifiers, notes or correspondence, DPIA screening is needed and a DPIA is likely required or strongly indicated where processing is likely high risk.
The ICO says DPIAs are required where processing is likely to result in high risk, and identifies innovative technology, sensitive data, large-scale processing and other risk indicators as relevant factors.
2. Medical-device questions may arise
Some AI tools used for image analysis, triage, diagnosis support or risk scoring may raise software-as-a-medical-device questions. ELSA AI does not determine medical-device status. That remains a regulatory/legal matter for the clinic, supplier and appointed advisers.
MHRA’s Yellow Card scheme allows reporting of safety concerns involving software, apps and AI used as medical devices. MHRA guidance also states that software and AI with a medical purpose and sufficient functionality may need UKCA or CE accreditation.
3. Reputational sensitivity is high
Dermatology, aesthetics, fertility and other specialist services often involve patients who expect a high standard of confidentiality. Uncontrolled AI use involving images, marketing tools, transcription or patient communication can create reputational risk as well as data protection and professional accountability questions.
4. Insurer, PMI, MDO and board scrutiny may follow
Where AI affects patient communication, diagnosis support, treatment planning, records or images, the clinic may need to evidence governance to insurers, PMI providers, MDOs, investors or board members. Gaps may affect indemnity support and should be clarified directly with the relevant MDO or insurer.
The typical governance position we find
In specialist clinics, common evidence gaps include:
- AI image-analysis or imaging-assisted tools are in clinical use, but vendor data evidence is not centrally held.
- Patient images are uploaded, transcribed or processed by AI without a documented patient transparency and consent position.
- Online triage, chat or consultation tools have been adopted without DPIA screening.
- Marketing AI tools are used across the patient journey without a written boundary between marketing data and clinical data.
- Clinicians use ChatGPT, Copilot or transcription tools informally on personal devices for drafting letters, summaries or treatment notes.
- Incident reporting does not cover AI-specific scenarios such as misclassification, hallucinated content, wrong-patient information or accidental exposure of images.
- There is no board-level view of AI exposure across clinical, admin and marketing workflows.
None of this means a breach has occurred. It means the clinic has a governance evidence gap and needs a documented position.
Common triggers for engaging ELSA AI
- Adoption of AI imaging or AI triage in a dermatology, aesthetics, ophthalmology or fertility setting.
- Insurer, PMI or MDO renewal questionnaire asking about AI tools.
- CQC inspection scheduled or anticipated.
- DPO requesting evidence on AI processing of patient images or sensitive data.
- Patient query, subject access request or complaint about AI use.
- Multi-site clinic group integrating AI tools across sites.
- Investor, acquirer or franchise-partner due diligence.
- Marketing or patient communication automation being introduced without a clinical-data boundary.
What ELSA AI delivers in four working days
The Specialist Clinic AI Governance Diagnostic™ produces a clear governance snapshot covering:
- which AI tools are used across clinical, admin, marketing and patient-facing workflows;
- whether patient images, identifiers, notes, correspondence or special category data are processed;
- whether tools are approved, conditional, tolerated, shadow or unknown;
- whether patient transparency and consent language is in place;
- whether DPIA screening has been completed and whether a full DPIA is likely required or strongly indicated;
- whether vendor DPAs, data residency, retention and sub-processor evidence are available;
- whether clinical AI outputs are reviewed by a qualified clinician before being relied on;
- whether incident reporting covers AI-specific scenarios;
- whether disclosure to the MDO, PMI or insurer warrants review;
- what should be done in the next 30 days.
What you receive
- Board / Clinic Owner Findings Report
- One-page RAG Exposure Map
- AI Tool and Use Case Inventory
- DPIA Readiness and Patient Data Exposure Note
- Vendor Data Position and Evidence Tracker
- Insurer / PMI / MDO Disclosure Readiness Note
- 30-Day Priority Action Plan
- Source and Guidance Mapping Appendix
Fee and timeline
Fixed fee: £4,500–£6,500 + VAT
Delivered within 4 working days from completed intake.
Multi-site or multi-specialty groups are scoped at intake.
The Clinical AI Safe Usage Launchpad™ is available to convert findings into a board-approved governance baseline over 4–6 weeks.
The AI Exposure Sentinel™ retainer keeps the evidence pack current from £950 per month.
What ELSA AI does not do
ELSA AI provides advisory governance support. We do not:
- approve AI tools or certify any vendor’s compliance position;
- determine whether a given AI tool is a medical device under MHRA rules;
- provide legal advice or regulatory sign-off;
- provide CQC, ICO or MHRA approval;
- determine insurer coverage, PMI position or MDO indemnity support;
- sign off clinical safety cases;
- replace the clinic’s DPO, legal counsel, clinical lead or accountable officers.
Final decisions remain with the clinic's accountable clinicians and appointed advisers.
Founder-delivered
Engagements are led by Faisal Ali, CISM, CRISC — Founder and Principal Consultant of ELSA AI — with more than two decades of experience in cybersecurity, information risk and AI governance across regulated environments.
Using AI with patient images, notes or specialist workflows?
Get a documented governance position before the next DPO review, inspection, renewal, patient query or board discussion.
Advisory governance support only. Not legal advice, CQC certification, ICO approval, MHRA approval, insurer coverage advice, MDO indemnity advice or clinical safety case sign-off. References to ICO, MHRA, CQC, NHS England and MDO guidance are made as governance-standard signals; this page does not constitute, and is not a substitute for, the clinic's own legal, regulatory or clinical safety review.